Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 188 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Minimal Residual Disease Clear all

Conditions: Colorectal Cancer, Minimal Residual Disease
Interventions: Fludarabine Phosphate, Cyclophosphamide, Cetuximab, TROP2-CAR-NK Cells, Rimiducid (AP1903), Lymphodepleting Chemotherapy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, Lymphocytic, Acute
Interventions: bone marrow aspiration, peripheral blood sampling; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Up to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Interventions: Blinatumomab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 28 Days and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Palo Alto, California • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Conditions: Colorectal Cancer
Interventions: TAS-102; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Myeloid Leukemia, Minimal Residual Disease
Interventions: Synthetic Tumor-Specific Breakpoint Peptide Vaccine; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Mosunetuzumab, ClonoSEQ; Drug · Device
Lead sponsor: Danielle Wallace; Other
Eligibility: 70 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Sotorasib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions: Dasatinib, Imatinib Mesylate, Nilotinib, Ruxolitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138; Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more

Conditions: Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions: Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Fludarabine, Rituximab; Radiation · Procedure · Biological + 1 more
Lead sponsor: Noah Merin; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Plasma Cell Myeloma
Interventions: Belantamab Mafodotin, Lenalidomide; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Myeloid Leukemia
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Myeloma Multiple
Interventions: Belantamab mafodotin, Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: DEC-C, MyeloSeq-HD; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Lymphoblastic Leukemia
Interventions: Obecabtagene Autoleucel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 40 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Duarte, California • Stanford, California • Basking Ridge, New Jersey + 6 more

Conditions: Multiple Myeloma
Interventions: Iberdomide, Daratumumab, Dexamethasone, Carfilzomib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more

Conditions: Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions: Lenalidomide; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
Interventions: clonoSEQ Assay; Diagnostic Test
Lead sponsor: Adaptive Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Stanford, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 10 more

Conditions: CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma
Interventions: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 6 Months to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hairy Cell Leukemia
Interventions: Cladribine, Rituximab, BMbx, MRI, EKG, Echocardiogram, Abdominal/splenic ultrasound, Stress test; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Treatment Free Observation; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Monroe, North Carolina • Philadelphia, Pennsylvania

Conditions: Relapsed Acute Lymphoblastic Leukemia, Relapsed Acute Myelogenous Leukemia
Interventions: GNKG168; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Large B-cell Lymphoma
Interventions: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™; Genetic · Drug · Device
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 64
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 52 more

Conditions: Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma, Metastatic Unresectable Sarcoma, Resectable Sarcoma, Colorectal Cancer
Interventions: Cisplatin, Isolated Chemotherapeutic Lung Perfusion, Metastasectomy; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

PRE-ISPY Phase I/II Oncology Platform Program

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

The clonoSEQ® Watch Registry

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases